Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades, the em...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrahennadi, Samitha, Sami, Amer, Manna, Mita, Pauls, Mehrnoosh, Ahmed, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161804/
https://www.ncbi.nlm.nih.gov/pubmed/34064867
http://dx.doi.org/10.3390/curroncol28030168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161804/
https://www.ncbi.nlm.nih.gov/pubmed/34064867
http://dx.doi.org/10.3390/curroncol28030168

Ejemplares similares